Cancer care demo: $111 million spent, but little benefit, critics say

Why This Topic Matters

The article highlights a payment and oversight dispute affecting oncology practices and Medicare spending. It matters to coders, compliance staff, and practice administrators who follow CMS demonstration programs, Medicare reimbursement, and oncology service reporting.

Article Sections

1. Overview of the cancer care demonstration controversy

   Introduces the Medicare demonstration project and summarizes the dispute over its purpose, cost, and perceived value. Sets up the roles of federal oversight, Congress, and oncology stakeholders.

2. IG evaluation and oncology response

   Summarizes the inspector general’s preliminary findings and the reaction from oncology organizations and CMS. Discusses the policy disagreement over how the project should be viewed within cancer care delivery and payment changes.

3. IG slams the project

   Presents the inspector general’s cost and payment concerns, including how the demonstration was structured and the scale of the payments involved. Also notes reported copay amounts and other findings described in the article.

4. Congressional reaction and next steps

   Describes House and Senate responses, including calls to continue or adjust the demonstration. Covers the broader legislative and oversight interest in the program.